Agendia signs US distribution deal for MammaPrint
This article was originally published in Clinica
Dutch firm Agendia (Amsterdam) has announced a US distribution agreement for its breast cancer microarray assay, MammaPrint. As of next month, The Molecular Profiling Institute (MPI), a CLIA-waived reference laboratory in Phoenix, Arizona, will become the sole provider of the breast cancer prognostic in the US. The product is already available in Europe and other international markets.